Johnson & Johnson temporarily paused the company’s Covid-19 vaccine candidate clinical trials due to an unexplained illness in a study participant, delaying one of the highest-profile efforts to contain the global pandemic.

South Korean drugmaker Daewoong Pharmaceutical Co. Ltd. received regulatory approval for Phase 1 clinical trials of the company’s anti-parasitic niclosamide drug to treat Covid-19 patients.

The global coronavirus death toll surpassed 1 million according to a Reuters tally, a bleak statistic in a pandemic that has devastated the global economy, overloaded health systems and turned daily life upside down.

The number of novel coronavirus cases in the United States topped 7 million – more than 20% of the world’s total – as Midwest states reported spikes in Covid-19 infections in September, according to a Reuters tally.

Global coronavirus cases exceeded 30 million, according to a Reuters tally, with the pandemic showing no signs of slowing.

AstraZeneca resumed British clinical trials of the company’s Covid-19 vaccine, one of the most advanced in development, after getting the green light from safety watchdogs.

Global coronavirus cases surged past 25 million, according to a Reuters tally, as India marked a worldwide record for daily new cases in the Covid-19 pandemic.

The global death toll from the coronavirus surpassed 800,000 according to a Reuters tally, with the United States, Brazil and India leading the rise in fatalities.

Global coronavirus cases pushed past 20 million, according to a Reuters tally, with the United States, Brazil and India accounting for more than half of all known infections.

Days after reports of Novavax Inc.’s experimental Covid-19 vaccine candidate producing antibodies in healthy patients in a clinical study, the company announced a license agreement with Serum Institute of India Private Limited (SIPL) to develop up to 1 billion doses of the preventative drug in India and other countries.